Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Neurochem Res ; 41(7): 1645-50, 2016 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-26980007

RESUMO

Granulocyte-colony stimulating factor (G-CSF) is widely known to have a neuroprotective effect, but its effects on function and morphology in mechanical nerve injury are not well understood. The aim of this study was to confirm the time course of the functional changes and morphological effects of G-CSF in a rat model of nerve crush injury. Twelve-eight rats were divided into three group: sham-operated control group, G-CSF-treated group, and saline treated group. 2 weeks after the nerve crush injury, G-CSF was injected for 5 days. After 4 weeks, functional tests such as motor nerve conduction velocity (MNCV), mechanical and cold allodynia tests, and morphological studies were performed. G-CSF-treated rats had significantly improved nerve function including MNCV and mechanical and cold allodynia. In addition, G-CSF-treated rats had significantly higher the density of myelinated fibers than saline-treated rats. In conclusion, we found that 100 µg/kg administration of G-CSF promoted long-term functional recovery in a rat model of nerve crush injury.


Assuntos
Fator Estimulador de Colônias de Granulócitos/uso terapêutico , Regeneração Nervosa/fisiologia , Fármacos Neuroprotetores/uso terapêutico , Neuropatia Ciática/tratamento farmacológico , Animais , Fator Estimulador de Colônias de Granulócitos/farmacologia , Masculino , Compressão Nervosa/métodos , Regeneração Nervosa/efeitos dos fármacos , Condução Nervosa/efeitos dos fármacos , Condução Nervosa/fisiologia , Fármacos Neuroprotetores/farmacologia , Distribuição Aleatória , Ratos , Ratos Sprague-Dawley , Neuropatia Ciática/patologia , Resultado do Tratamento
2.
Cardiovasc Diabetol ; 10: 92, 2011 Oct 17.
Artigo em Inglês | MEDLINE | ID: mdl-21999467

RESUMO

BACKGROUND: Diabetic cardiomyopathy (CMP) is a common and disabling disease in diabetic patients, however no effective treatments have been developed. Although granulocyte-colony stimulating factor (G-CSF) improves heart function in myocardial infarction, its effect on non-ischemic CMP such as diabetic CMP is unknown. In the present study, we investigated the effects of G-CSF on diabetic CMP in a rat model of type II diabetes. METHODS: Twenty 7-week-old male Otsuka Long-Evans Tokushima Fatty (OLETF: a rat model of diabetes) rats and 10 male Long-Evans Tokushima Otsuka (LETO: normal controls) rats were used. All of the LETO and 8 OLETF rats were fed on tap water while the rest were fed on sucrose-containing water. After 10 weeks, saline or recombinant human G-CSF (100 µg/kg/day) was injected intraperitoneally for 5 days. Blood levels of glucose, total cholesterol and triglyceride, and Doppler echocardiograms for diastolic dysfunction were obtained just before and 4 weeks after the saline or G-CSF treatment. Light microscopy, electron microscopy (EM) and immunohistochemistry for transforming growth factor-ß were employed to examine myocardial histology 4 weeks after the saline or G-CSF treatment. RESULTS: Diastolic dysfunction developed at 17 weeks (before the saline or G-CSF treatment) in the OLETF rats whether or not they were fed sucrose water, but were more severe in those fed sucrose water. Four weeks after saline or G-CSF treatment, diastolic function had recovered in the G-CSF-treated group regardless of sucrose water feeding, and perivascular and/or interstitial fibrosis in the G-CSF-treated group had decreased significantly. TGF-ß immunoreactivity in the interstitial and perivascular tissue was also reduced in the G-CSF-treated group, and EM studies revealed less severe disruption of myofilaments and mitochondrial cristae, and decreased collagen deposition. CONCLUSIONS: G-CSF can ameliorate cardiac diastolic dysfunction and morphological damage, especially fibrosis of the myocardium, in OLETF rats with diabetic CMP.


Assuntos
Diabetes Mellitus Tipo 2/tratamento farmacológico , Cardiomiopatias Diabéticas/tratamento farmacológico , Fator Estimulador de Colônias de Granulócitos/uso terapêutico , Insuficiência Cardíaca/tratamento farmacológico , Animais , Diabetes Mellitus Tipo 2/patologia , Diabetes Mellitus Tipo 2/fisiopatologia , Cardiomiopatias Diabéticas/patologia , Cardiomiopatias Diabéticas/fisiopatologia , Fibrose Endomiocárdica/tratamento farmacológico , Fibrose Endomiocárdica/patologia , Fibrose Endomiocárdica/fisiopatologia , Insuficiência Cardíaca/patologia , Insuficiência Cardíaca/fisiopatologia , Humanos , Masculino , Ratos , Ratos Endogâmicos OLETF , Ratos Long-Evans
3.
Mol Cell Endocrinol ; 414: 64-72, 2015 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-26190836

RESUMO

Effective treatment of diabetic neuropathy (DN) remains unsolved. We serendipitously observed dramatic relief of pain in several patients with painful DN receiving granulocyte-colony stimulating factor (G-CSF). The aim of this study was to determine if G-CSF could treat DN in an animal model and to ascertain its mechanism of action. In a rodent model of DN, G-CSF dramatically recovered nerve function, retarded histological nerve changes and increased the expression of neurotrophic factors within nerve. A sex-mismatched bone marrow transplantation (BMT) study revealed that G-CSF treatment increased the abundance of bone marrow (BM)-derived cells in nerves damaged by DN. However, we did not observe evidence of transdifferentiation or cell fusion of BM-derived cells. The beneficial effects of G-CSF were dependent on the integrity of BM. In conclusion, G-CSF produced a therapeutic effect in a rodent model of DN, which was attributed, at least in part, to the actions of BM-derived cells.


Assuntos
Potenciais de Ação/efeitos dos fármacos , Células da Medula Óssea/efeitos dos fármacos , Neuropatias Diabéticas/tratamento farmacológico , Fator Estimulador de Colônias de Granulócitos/administração & dosagem , Animais , Células da Medula Óssea/citologia , Transplante de Medula Óssea , Neuropatias Diabéticas/fisiopatologia , Modelos Animais de Doenças , Feminino , Fator Estimulador de Colônias de Granulócitos/farmacologia , Humanos , Masculino , Fatores de Crescimento Neural/efeitos dos fármacos , Fatores de Crescimento Neural/genética , Fatores de Crescimento Neural/metabolismo , Ratos
4.
Cell Transplant ; 21(8): 1687-96, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22776022

RESUMO

Human amniotic epithelial cells (h-AECs), which have various merits as a cell source for cell therapy, are known to differentiate into cardiomyocytes in vitro. However, the ability of h-AECs to differentiate into cardiomyocytes in vivo and their cell transplantation effects on myocardial infarction are still unknown. In this study, we assessed whether h-AECs could differentiate into cardiomyocytes in vivo and whether h-AECs transplantation can decrease infarct size and improve cardiac function, in comparison to transplantation of cord blood-derived mesenchymal stem cells (MSCs) or adipose tissue-derived MSCs. For our study, we injected h-AECs, cord blood-derived MSCs, adipose tissue-derived MSCs, and saline into areas of myocardial infarction in athymic nude rats. After 4 weeks, 3% of the surviving h-AECs expressed myosin heavy chain, a marker specific to the myocardium. Compared with the saline group, all cell-implanted groups showed a higher ejection fraction, lower infarct area by positron emission tomography and histology, and more abundant myocardial gene and protein expression in the infarct area. We showed that h-AECs can differentiate into cardiomyocyte-like cells, decrease infarct size, and improve cardiac function in vivo. The beneficial effects of h-AECs were comparable to those of cord blood and adipose tissue-derived MSCs. These results support the need for further studies of h-AECs as a cell source for myocardial regeneration due to their plentiful availability, low immunity, and lack of ethical issues related to their use.


Assuntos
Tecido Adiposo/citologia , Âmnio/citologia , Células Epiteliais/citologia , Sangue Fetal/citologia , Células-Tronco Mesenquimais/citologia , Infarto do Miocárdio/terapia , Miócitos Cardíacos/metabolismo , Animais , Diferenciação Celular , Ecocardiografia , Células Epiteliais/transplante , Humanos , Masculino , Transplante de Células-Tronco Mesenquimais , Infarto do Miocárdio/diagnóstico por imagem , Infarto do Miocárdio/patologia , Cadeias Pesadas de Miosina/metabolismo , Tomografia por Emissão de Pósitrons , Radiografia , Ratos , Ratos Nus
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA